{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:46:23Z","timestamp":1785905183639,"version":"3.56.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research","doi-asserted-by":"publisher","award":["SUG-2024-1119"],"award-info":[{"award-number":["SUG-2024-1119"]}],"id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.molpha.2026.100131","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:14:59Z","timestamp":1780067699000},"page":"100131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of GPR55 in glutamatergic and dopaminergic signaling: A review of preclinical evidence in neuropsychiatric disorders"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8793-3318","authenticated-orcid":false,"given":"Sanjay N.","family":"Awathale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik T.","family":"Nakhate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji R.","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer N.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.molpha.2026.100131_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0169-328X(98)00277-0","article-title":"Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain","volume":"64","author":"Sawzdargo","year":"1999","journal-title":"Brain Res Mol Brain Res"},{"issue":"6","key":"10.1016\/j.molpha.2026.100131_bib3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.tips.2018.02.011","article-title":"Lysophosphatidylinositols, from cell membrane constituents to GPR55 ligands","volume":"39","author":"Alhouayek","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.molpha.2026.100131_bib4","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.0711278105","article-title":"GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current","volume":"105","author":"Lauckner","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.molpha.2026.100131_bib5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.molpha.2026.100131_bib6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/1570159X14666160729155441","article-title":"Advances in the physiology of GPR55 in the central nervous system","volume":"15","author":"Marichal-Cancino","year":"2017","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41422-024-01044-w","article-title":"Structural insight into GPR55 ligand recognition and G-protein coupling","volume":"35","author":"Xia","year":"2025","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2005.11.003","article-title":"In silico patent searching reveals a new cannabinoid receptor","volume":"27","author":"Baker","year":"2006","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.molpha.2026.100131_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s12035-026-05780-5","article-title":"Neuroprotective role of cannabinoid CB1 and GPR55 receptors in a cell model of multiple sclerosis","volume":"63","author":"Mart\u00ednez-Pinilla","year":"2026","journal-title":"Mol Neurobiol"},{"issue":"8","key":"10.1016\/j.molpha.2026.100131_bib12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.molpha.2026.100131_bib13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fpsyt.2018.00767","article-title":"Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies","volume":"9","author":"Li","year":"2019","journal-title":"Front Psychiatry"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.molpha.2026.100131_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/7854_2015_5004","article-title":"Translational assessment of reward and motivational deficits in psychiatric disorders","volume":"28","author":"Der-Avakian","year":"2016","journal-title":"Curr Top Behav Neurosci"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41398-024-02820-3","article-title":"GPR55 is expressed in glutamate neurons and functionally modulates drug taking and seeking in rats and mice","volume":"14","author":"He","year":"2024","journal-title":"Transl Psychiatry"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/can.2016.0030","article-title":"Palmitoylethanolamide modulates GPR55 receptor signaling in the ventral hippocampus to regulate mesolimbic dopamine activity, social interaction, and memory processing","volume":"2","author":"Kramar","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"issue":"11","key":"10.1016\/j.molpha.2026.100131_bib18","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s00213-021-05949-x","article-title":"Cannabinoid receptor GPR55 activation blocks nicotine use disorder by regulation of AMPAR phosphorylation","volume":"238","author":"Liu","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.molpha.2026.100131_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fphar.2012.00182","article-title":"Group 1 metabotropic glutamate receptor function and its regulation of learning and memory in the aging brain","volume":"3","author":"M\u00e9nard","year":"2012","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.molpha.2026.100131_bib21","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1055\/s-0031-1273707","article-title":"Effects of dopamine and glutamate on synaptic plasticity: a computational modeling approach for drug abuse as comorbidity in mood disorders","volume":"44","author":"Qi","year":"2011","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1016\/j.molpha.2026.100131_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/1566524023361961","article-title":"Synaptic plasticity in drug reward circuitry","volume":"2","author":"Winder","year":"2002","journal-title":"Curr Mol Med"},{"issue":"13","key":"10.1016\/j.molpha.2026.100131_bib24","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1073\/pnas.1211204110","article-title":"Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses","volume":"110","author":"Sylantyev","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.molpha.2026.100131_bib25","doi-asserted-by":"crossref","first-page":"304","DOI":"10.55782\/ane-2022-029","article-title":"Central GPR55 may prevent nicotine reinforcing actions: a preliminary study","volume":"82","author":"D\u00edaz-Barba","year":"2022","journal-title":"Acta Neurobiol Exp (Wars)"},{"issue":"8","key":"10.1016\/j.molpha.2026.100131_bib27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.neuron.2023.01.018","article-title":"Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity","volume":"111","author":"Rosenberg","year":"2023","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.molpha.2026.100131_bib29","article-title":"GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.molpha.2026.100131_bib30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.pharep.2015.12.009","article-title":"The effect of O-1602, an atypical cannabinoid, on morphine-induced conditioned place preference and physical dependence","volume":"68","author":"Alavi","year":"2016","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.molpha.2026.100131_bib31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bjp.0707419","article-title":"The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects","volume":"152","author":"Johns","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.molpha.2026.100131_bib32","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s11481-012-9351-6","article-title":"The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55","volume":"7","author":"Sharir","year":"2012","journal-title":"J Neuroimmune Pharmacol"},{"issue":"4","key":"10.1016\/j.molpha.2026.100131_bib33","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.bbrc.2007.08.078","article-title":"Identification of GPR55 as a lysophosphatidylinositol receptor","volume":"362","author":"Oka","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10.1016\/j.molpha.2026.100131_bib35","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1111\/bph.13107","article-title":"The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells","volume":"172","author":"AlSuleimani","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1096\/fj.08-108670","article-title":"The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation","volume":"23","author":"Henstridge","year":"2009","journal-title":"FASEB J"},{"issue":"23","key":"10.1016\/j.molpha.2026.100131_bib37","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1111\/bph.12850","article-title":"Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling","volume":"171","author":"Balenga","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"43","key":"10.1016\/j.molpha.2026.100131_bib38","doi-asserted-by":"crossref","first-page":"29817","DOI":"10.1074\/jbc.M109.050187","article-title":"Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands","volume":"284","author":"Kapur","year":"2009","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.molpha.2026.100131_bib39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jb\/mvp208","article-title":"Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells","volume":"147","author":"Oka","year":"2010","journal-title":"J Biochem"},{"issue":"3","key":"10.1016\/j.molpha.2026.100131_bib40","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1476-5381.2009.00625.x","article-title":"GPR55 ligands promote receptor coupling to multiple signalling pathways","volume":"160","author":"Henstridge","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1074\/jbc.M111.296020","article-title":"Modulation of L-\u03b1-lysophosphatidylinositol\/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids","volume":"287","author":"Anavi-Goffer","year":"2012","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.molpha.2026.100131_bib42","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1111\/j.1476-5381.2011.01562.x","article-title":"The GPCR-associated sorting protein 1 regulates ligand-induced down-regulation of GPR55","volume":"165","author":"Kargl","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.molpha.2026.100131_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/syn.20821","article-title":"Functional polymorphism in the GPR55 gene is associated with anorexia nervosa","volume":"65","author":"Ishiguro","year":"2011","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.molpha.2026.100131_bib44","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s13311-018-0610-y","article-title":"Alterations in gene and protein expression of cannabinoid CB2 and GPR55 receptors in the dorsolateral prefrontal cortex of suicide victims","volume":"15","author":"Garc\u00eda-Guti\u00e9rrez","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.molpha.2026.100131_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122195","article-title":"Modulation of PI3K\/Akt\/GSK3\u03b2 signaling cascade through G protein-coupled receptor 55 (GPR55) activation: prenatal lysophosphatidylinositol attenuates valproic acid-induced synaptic abnormalities and mitochondrial dysfunction","volume":"334","author":"Ahmed","year":"2023","journal-title":"Life Sci"},{"issue":"18","key":"10.1016\/j.molpha.2026.100131_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810932","article-title":"Lysophosphatidylinositol induced morphological changes and stress fiber formation through the GPR55-RhoA-ROCK pathway","volume":"23","author":"Nakajima","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.molpha.2026.100131_bib47","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3389\/fphar.2020.01002","article-title":"O-1602, an agonist of atypical cannabinoid receptors GPR55, reverses the symptoms of depression and detrusor overactivity in rats subjected to corticosterone treatment","volume":"11","author":"Wr\u00f3bel","year":"2020","journal-title":"Front Pharmacol"},{"issue":"52","key":"10.1016\/j.molpha.2026.100131_bib48","doi-asserted-by":"crossref","first-page":"9456","DOI":"10.1021\/bi4008885","article-title":"Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands","volume":"52","author":"Kotsikorou","year":"2013","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2011.06.004","article-title":"The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55","volume":"500","author":"Schuelert","year":"2011","journal-title":"Neurosci Lett"},{"issue":"13","key":"10.1016\/j.molpha.2026.100131_bib50","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.3390\/ijms25137358","article-title":"GPR55 antagonist CID16020046 attenuates obesity-induced airway inflammation by suppressing chronic low-grade inflammation in the lungs","volume":"25","author":"Son","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.molpha.2026.100131_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.945836","article-title":"Intrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats","volume":"13","author":"Patricio","year":"2022","journal-title":"Front Pharmacol"},{"issue":"38","key":"10.1016\/j.molpha.2026.100131_bib52","doi-asserted-by":"crossref","first-page":"16511","DOI":"10.1073\/pnas.0902743106","article-title":"The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo","volume":"106","author":"Whyte","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.molpha.2026.100131_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105176","article-title":"Molecular insights into GPCR mechanisms for drugs of abuse","volume":"299","author":"Sanchez-Reyes","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.molpha.2026.100131_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116742","article-title":"CBD and the 5-HT1A receptor: a medicinal and pharmacological review","volume":"233","author":"Alexander","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.molpha.2026.100131_bib55","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2147\/JPR.S258433","article-title":"CBD effects on TRPV1 signaling pathways in cultured DRG neurons","volume":"13","author":"Anand","year":"2020","journal-title":"J Pain Res"},{"key":"10.1016\/j.molpha.2026.100131_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154771","article-title":"Cannabidiol goes nuclear: the role of PPAR\u03b3","volume":"114","author":"Khosropoor","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.molpha.2026.100131_bib57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neuroscience.2025.06.016","article-title":"ML184 influences coping strategies via GPR55-dependent mechanisms following its delivery in the periaqueductal gray (PAG) region","volume":"580","author":"L\u00f3pez-Lariz","year":"2025","journal-title":"Neuroscience"},{"issue":"16","key":"10.1016\/j.molpha.2026.100131_bib58","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.3390\/ijms21165922","article-title":"The role of atypical cannabinoid ligands O-1602 and O-1918 on skeletal muscle homeostasis with a focus on obesity","volume":"21","author":"Simcocks","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/neu.2020.30","article-title":"The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson\u2019s disease rat model","volume":"33","author":"Fatemi","year":"2021","journal-title":"Acta Neuropsychiatr"},{"issue":"5","key":"10.1016\/j.molpha.2026.100131_bib60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3892\/mmr.2022.12671","article-title":"CID16020046, a GPR55 antagonist, attenuates sepsis-induced acute kidney injury","volume":"25","author":"Chen","year":"2022","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.molpha.2026.100131_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109088","article-title":"The GPR55 antagonist CID16020046 mitigates advanced glycation end products (AGEs)-induced chondrocyte activation","volume":"325","author":"Zeng","year":"2020","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib62","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/s41467-025-57204-y","article-title":"Structural basis for lipid-mediated activation of G protein-coupled receptor GPR55","volume":"16","author":"Claff","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.molpha.2026.100131_bib63","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/mp.2017.249","article-title":"Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention","volume":"23","author":"Lieberman","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.molpha.2026.100131_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110636","article-title":"GPR55 activation prevents amphetamine-induced conditioned place preference and decrease the amphetamine-stimulated inflammatory response in the ventral hippocampus in male rats","volume":"120","author":"S\u00e1nchez-Zavaleta","year":"2023","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.molpha.2026.100131_bib65","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tips.2008.12.004","article-title":"The enigmatic pharmacology of GPR55","volume":"30","author":"Ross","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/wps.20494","article-title":"Reward-related cognitive vulnerability to bipolar spectrum disorders","volume":"17","author":"Alloy","year":"2018","journal-title":"World Psychiatry"},{"issue":"434","key":"10.1016\/j.molpha.2026.100131_bib68","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0447.2007.01058.x","article-title":"Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder","author":"Berk","year":"2007","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"2","key":"10.1016\/j.molpha.2026.100131_bib69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainresrev.2009.05.005","article-title":"Emerging role of glutamate in the pathophysiology of major depressive disorder","volume":"61","author":"Hashimoto","year":"2009","journal-title":"Brain Res Rev"},{"issue":"8","key":"10.1016\/j.molpha.2026.100131_bib70","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00702-014-1180-8","article-title":"Glutamate as a neurotransmitter in the healthy brain","volume":"121","author":"Zhou","year":"2014","journal-title":"J Neural Transm (Vienna)"},{"issue":"6\u20137","key":"10.1016\/j.molpha.2026.100131_bib71","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuint.2007.03.012","article-title":"The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention","volume":"51","author":"Sheldon","year":"2007","journal-title":"Neurochem Int"},{"issue":"27","key":"10.1016\/j.molpha.2026.100131_bib72","doi-asserted-by":"crossref","first-page":"E2518","DOI":"10.1073\/pnas.1306832110","article-title":"A\u03b2 induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss","volume":"110","author":"Talantova","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.molpha.2026.100131_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.585584","article-title":"Molecular mechanisms of glutamate toxicity in Parkinson\u2019s disease","volume":"14","author":"Wang","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.molpha.2026.100131_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110423","article-title":"Activation of GPR55 attenuates cognitive impairment and neurotoxicity in a mouse model of Alzheimer\u2019s disease induced by A\u03b21\u201342 through inhibiting RhoA\/ROCK2 pathway","volume":"112","author":"Xiang","year":"2022","journal-title":"Progress Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.molpha.2026.100131_bib75","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biology12060805","article-title":"The expression of the endocannabinoid receptors CB2 and GPR55 is highly increased during the progression of Alzheimer\u2019s disease in AppNL-G-F knock-in mice","volume":"12","author":"Medina-Vera","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.molpha.2026.100131_bib76","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13041-017-0318-7","article-title":"The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress","volume":"10","author":"Shi","year":"2017","journal-title":"Mol Brain"},{"key":"10.1016\/j.molpha.2026.100131_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105743","article-title":"The neuroprotective effects of GPR55 against hippocampal neuroinflammation and impaired adult neurogenesis in CSDS mice","volume":"169","author":"Shen","year":"2022","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.molpha.2026.100131_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1130989","article-title":"Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories","volume":"14","author":"Hassamal","year":"2023","journal-title":"Front Psychiatry"},{"issue":"7215","key":"10.1016\/j.molpha.2026.100131_bib79","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature07455","article-title":"The molecular neurobiology of depression","volume":"455","author":"Krishnan","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(02)00653-0","article-title":"Neurobiology of depression","volume":"34","author":"Nestler","year":"2002","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.molpha.2026.100131_bib81","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/clpt.2011.282","article-title":"The epigenetic code in depression: implications for treatment","volume":"91","author":"Schroeder","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.molpha.2026.100131_bib82","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s11064-010-0169-4","article-title":"Effects of depressive-like behavior of rats on brain glutamate uptake","volume":"35","author":"Almeida","year":"2010","journal-title":"Neurochem Res"},{"issue":"5","key":"10.1016\/j.molpha.2026.100131_bib83","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1399-5618.2010.00838.x","article-title":"Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder","volume":"12","author":"Altshuler","year":"2010","journal-title":"Bipolar Disord"},{"issue":"6","key":"10.1016\/j.molpha.2026.100131_bib84","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/mp.2010.44","article-title":"Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression","volume":"16","author":"Bernard","year":"2011","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.molpha.2026.100131_bib85","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11064-011-0404-7","article-title":"Chronic stress and lithium treatments alter hippocampal glutamate uptake and release in the rat and potentiate necrotic cellular death after oxygen and glucose deprivation","volume":"36","author":"de Vasconcellos-Bittencourt","year":"2011","journal-title":"Neurochem Res"},{"issue":"1\u20133","key":"10.1016\/j.molpha.2026.100131_bib86","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jad.2010.06.003","article-title":"Glial and glutamatergic markers in depression, alcoholism, and their comorbidity","volume":"127","author":"Miguel-Hidalgo","year":"2010","journal-title":"J Affect Disord"},{"issue":"2","key":"10.1016\/j.molpha.2026.100131_bib87","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.neuropharm.2009.09.005","article-title":"Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression","volume":"58","author":"Zink","year":"2010","journal-title":"Neuropharmacology"},{"issue":"2\u20133","key":"10.1016\/j.molpha.2026.100131_bib88","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0014-2999(97)00143-X","article-title":"Histamine modulation of glutamate release from hippocampal synaptosomes","volume":"323","author":"Rodriguez","year":"1997","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib89","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41531-023-00586-x","article-title":"Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson\u2019s disease patients","volume":"9","author":"L\u00f3pez-Aguirre","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"10.1016\/j.molpha.2026.100131_bib90","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/mp.2013.3","article-title":"Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson\u2019s disease","volume":"19","author":"Drui","year":"2014","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib91","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/molecules23010040","article-title":"Dopamine and levodopa prodrugs for the treatment of Parkinson\u2019s disease","volume":"23","author":"Haddad","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.molpha.2026.100131_bib92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnins.2020.00025","article-title":"Neuropsychiatric disorders in Parkinson\u2019s disease: what do we know about the role of dopaminergic and non-dopaminergic systems?","volume":"14","author":"Dujardin","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.molpha.2026.100131_bib93","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neuropharm.2017.08.017","article-title":"GPR55: a therapeutic target for Parkinson\u2019s disease?","volume":"125","author":"Celorrio","year":"2017","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.molpha.2026.100131_bib94","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/jnnp.2010.213652","article-title":"Depression and anxiety related subtypes in Parkinson\u2019s disease","volume":"82","author":"Brown","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"24","key":"10.1016\/j.molpha.2026.100131_bib96","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.3390\/molecules26247643","article-title":"Preclinical investigation in neuroprotective effects of the GPR55 ligand VCE-006.1 in experimental models of Parkinson\u2019s disease and amyotrophic lateral sclerosis","volume":"26","author":"Burgaz","year":"2021","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.molpha.2026.100131_bib97","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00406-024-01788-x","article-title":"Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication","volume":"275","author":"Haddad","year":"2025","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"7","key":"10.1016\/j.molpha.2026.100131_bib98","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40263-018-0539-z","article-title":"Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention","volume":"32","author":"Leweke","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.molpha.2026.100131_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110553","article-title":"HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia","volume":"117","author":"Cortez","year":"2022","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib100","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/biom12010108","article-title":"Early blockade of CB1 receptors ameliorates schizophrenia-like alterations in the neurodevelopmental MAM model of schizophrenia","volume":"12","author":"Stark","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54604-4","article-title":"Synaptotagmin-11 deficiency mediates schizophrenia-like behaviors in mice via dopamine over-transmission","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.molpha.2026.100131_bib104","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/schbul\/sbs062","article-title":"Glutamate dysfunction in hippocampus: relevance of dentate gyrus and CA3 signaling","volume":"38","author":"Tamminga","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.molpha.2026.100131_bib106","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.expneurol.2014.06.017","article-title":"CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum","volume":"261","author":"Mart\u00ednez-Pinilla","year":"2014","journal-title":"Exp Neurol"},{"issue":"suppl 1","key":"10.1016\/j.molpha.2026.100131_bib107","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.21037\/tp.2019.09.09","article-title":"Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation","volume":"9","author":"Hodges","year":"2020","journal-title":"Transl Pediatr"},{"issue":"12","key":"10.1016\/j.molpha.2026.100131_bib108","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1038\/s41380-024-02614-5","article-title":"Modulation of neuroinflammation and oxidative stress by targeting GPR55\u2014new approaches in the treatment of psychiatric disorders","volume":"29","author":"Apweiler","year":"2024","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.molpha.2026.100131_bib109","first-page":"101","article-title":"GPR55 is expressed in glutamate neurons and functionally modulates nicotine taking and seeking in rats and mice","volume":"14","author":"Xi","year":"2023","journal-title":"Res Sq"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X26000313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X26000313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:02:23Z","timestamp":1785902543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X26000313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":98,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0026895X26000313"],"URL":"https:\/\/doi.org\/10.1016\/j.molpha.2026.100131","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of GPR55 in glutamatergic and dopaminergic signaling: A review of preclinical evidence in neuropsychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molpha.2026.100131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100131"}}